Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Clopidogrel Viatris (previously Clopidogrel Taw Pharma)“
Suchtreffer
Begriffe & Kennungen
Clopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Medicinal products that are strong or moderate CYP2C19 inhibitors include for example omeprazole and esomepraz
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · NSAIDs: in a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Oral anticoagulants: the concomitant administration of clopidogrel with oral anticoagulants is not recommended
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Other concomitant therapy:
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other co
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Proton Pump Inhibitors (PPI): Omeprazole 80 mg once daily administered either at the same time as clopidogrel
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Rifampicin strongly induces CYP2C19, resulting in both an increased level of clopidogrel active metabolite and
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Rosuvastatin: Clopidogrel has been shown to increase rosuvastatin exposure in patients by 2-fold (AUC) and 1.3
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · SSRIs: since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administratio
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · The pharmacokinetics of digoxin or theophylline were not modified by the co-administration of clopidogrel. Ant
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers or antacids in
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Thrombolytics: the safety of the concomitant administration of clopidogrel, fibrin or non-fibrin specific thro
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.8 Undesirable effects · 1
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.8 · 10 System Organ Common Uncommon Rare Very rare, not known* Class Immune system Serum sickness, disorders anaph
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.8 · 11 System Organ Common Uncommon Rare Very rare, not known* Class Skin and Bruising Rash, pruritus, skin Bullou
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.8 · 9 In COMMIT, the overall rate of noncerebral major bleeding or cerebral bleeding was low and similar in both g
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.8 · Bleeding is the most common reaction reported both in clinical studies as well as in post-marketing experience
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.8 · Ear and labyrinth Vertigo disorders Vascular Haematoma Serious haemorrhage, disorders haemorrhage of operative
Eintrag öffnen